M

Madrigal Pharmaceuticals
D

MDGL

478.50
USD
-4.18
(-0.87%)
مغلق
حجم التداول
22,040
الربح لكل سهم
-4
العائد الربحي
-
P/E
-37
حجم السوق
10,867,414,470
أصول ذات صلة المقالات

العنوان: Madrigal Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.